Novo Nordisk A/S (NVO) — closed signal from March 26, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 24, 2026.
Predicted vs. what happened
NVO price · publication thesis → realized outcomesplit-adjusted
$35.50 – $37.20Entry zone — fair-value band
$36.83Published — price the day we called it
$40.88Target — the price the thesis aimed for
$47.79Peak — highest point inside the window, not a realized return
$47.41Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 21 days.
Peak price
$47.79
peak on May 11, 2026 — not a realized returnPeak gain
+29.8%
peak, from the publication priceWindow close
$47.41
end-of-window price, context onlyDays to target
21
Window
March 26, 2026 – June 24, 2026
The thesis — published March 26, 2026
Predicted growth
+11%
over the measurement windowTarget price
$40.88
the price the thesis aimed forEntry zone
$35.50 – $37.20
the fair-value band we waited forPrice at publication
$36.83
published March 26, 2026Confidence
68%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novo Nordisk still runs a strong business in diabetes and obesity, but recent negative news and a downgrade have pushed sentiment lower. Shares have dropped well below their recent trend, creating a situation where a rebound is possible if the stock settles down. Confidence is cautious until the downgrade impact lessens and the price shows clearer signs of repair.
Primary drivers
- The diabetes and obesity business remains a lasting strength
- The downgrade made the stock more beaten down lately
- Shares traded noticeably below the recent trend after the pullback
- A steadier mood in the market would lift rebound chances
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.